このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Aytu BioPharma 将来の成長

Future 基準チェック /36

Aytu BioPharmaの収益は年間9.9%で減少すると予測されていますが、年間利益は年間98.4%で増加すると予想されています。EPS は年間99%で増加すると予想されています。

主要情報

96.2%

収益成長率

97.2%

EPS成長率

Pharmaceuticals 収益成長	27.6%
収益成長率	-9.9%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	20 Jun 2024

今後の成長に関する最新情報

US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results

Feb 17

Recent updates

It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This Year

Jun 20

Here's Why Aytu BioPharma (NASDAQ:AYTU) Has A Meaningful Debt Burden

Jun 14

US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results

Feb 17

Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Feb 16

Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?

Jan 23

Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Share Price Boosted 59% But Its Business Prospects Need A Lift Too

Sep 29

Aytu stock falls amid suspending clinical programs to save costs

Oct 13

Aytu BioScience GAAP EPS of -$0.49 misses by $0.12, revenue of $27.45M beats by $1.95M

Sep 27

Aytu Biopharma adds fourth patent license for AR101 to treat rare genetic disorder

Sep 14

Aytu gets US patent for AR101/Enzastaurin for circulatory system disorders

Aug 16

Aytu BioPharma plunges on pricing $10M stock and warrants offering

Aug 09

Earnings Release: Here's Why Analysts Cut Their Aytu BioPharma, Inc. (NASDAQ:AYTU) Price Target To US$8.00

May 19

Is Aytu Biopharma (NASDAQ:AYTU) Using Debt In A Risky Way?

Sep 11

Aytu BioPharma up 21% in afternoon trading

Jun 21

Increases to Aytu Biopharma, Inc.'s (NASDAQ:AYTU) CEO Compensation Might Cool off for now

May 15

業績と収益の成長予測

NasdaqCM:AYTU - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
6/30/2026	72	1	N/A	N/A	1
6/30/2025	78	4	N/A	N/A	1
6/30/2024	81	-14	N/A	N/A	1
3/31/2024	94	-14	9	9	N/A
12/31/2023	98	-18	6	6	N/A
9/30/2023	102	-24	4	4	N/A
6/30/2023	107	-17	-5	-5	N/A
3/31/2023	104	-31	-22	-22	N/A
12/31/2022	106	-77	-28	-28	N/A
9/30/2022	102	-82	-34	-34	N/A
6/30/2022	97	-109	-29	-29	N/A
3/31/2022	93	-112	-30	-28	N/A
12/31/2021	82	-84	-30	-28	N/A
9/30/2021	74	-82	-24	-22	N/A
6/30/2021	66	-58	-28	-26	N/A
3/31/2021	57	-42	-27	-27	N/A
12/31/2020	52	-22	-30	-30	N/A
9/30/2020	40	-13	-33	-33	N/A
6/30/2020	28	-14	-28	-28	N/A
3/31/2020	14	-25	-24	-24	N/A
12/31/2019	9	-24	-16	-16	N/A
9/30/2019	7	-29	-14	-14	N/A
6/30/2019	7	-27	-14	-14	N/A
3/31/2019	7	-12	-16	-15	N/A
12/31/2018	5	-10	-17	-16	N/A
9/30/2018	4	-9	-15	-14	N/A
6/30/2018	4	-10	-16	-16	N/A
3/31/2018	4	-17	-15	-15	N/A
12/31/2017	4	-20	N/A	-13	N/A
9/30/2017	4	-21	N/A	-13	N/A
6/30/2017	3	-23	N/A	-14	N/A
3/31/2017	3	-31	N/A	-13	N/A
12/31/2016	3	-33	N/A	-13	N/A
9/30/2016	3	-32	N/A	-14	N/A
6/30/2016	3	-28	N/A	-11	N/A
3/31/2016	2	-15	N/A	-10	N/A
12/31/2015	1	-10	N/A	-9	N/A
9/30/2015	1	-8	N/A	-7	N/A
6/30/2015	0	-8	N/A	-7	N/A
3/31/2015	0	-7	N/A	-7	N/A
12/31/2014	0	-7	N/A	-7	N/A
6/30/2014	0	-6	N/A	-6	N/A
12/31/2013	0	-4	N/A	-4	N/A
6/30/2013	0	-3	N/A	-3	N/A

アナリストによる今後の成長予測

収入対貯蓄率: AYTUは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.4% ) よりも高い成長率であると考えられます。

収益対市場: AYTU今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: AYTU今後 3 年以内に収益を上げることが予想されます。

収益対市場: AYTUの収益は今後 3 年間で減少すると予想されています (年間-9.9% )。

高い収益成長: AYTUの収益は今後 3 年間で減少すると予測されています (年間-9.9% )。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: AYTUの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Aytu BioPharma 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Consensus EPS estimates fall by 12%

US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results

Price target decreased by 95% to US$5.00

Forecast to breakeven in 2025

Consensus EPS estimates fall by 31%

Forecast to breakeven in 2024

Recent updates

New minor risk - Shareholder dilution

It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This Year

Here's Why Aytu BioPharma (NASDAQ:AYTU) Has A Meaningful Debt Burden

Consensus EPS estimates fall by 12%

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Aytu BioPharma, Inc., Annual General Meeting, Jun 26, 2024

Aytu BioPharma, Inc. to Report Q3, 2024 Results on May 15, 2024

US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results

Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Aytu BioPharma, Inc. to Report Q2, 2024 Results on Feb 14, 2024

Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?

Price target decreased by 95% to US$5.00

Aytu BioPharma, Inc. to Report Q1, 2024 Results on Nov 14, 2023

Aytu BioPharma, Inc. Announces Approval of the Cotempla XR-ODT Manufacturing Site Transfer Prior Approval Supplement

Aytu BioPharma, Inc. announced delayed annual 10-K filing

Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Share Price Boosted 59% But Its Business Prospects Need A Lift Too

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Aytu BioPharma, Inc. to Report Q4, 2023 Results on Sep 27, 2023

Aytu BioPharma, Inc. Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement

Aytu BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $3.999955 million.

Aytu BioPharma, Inc. Appoints Abhinav "Abi" Jain as Board of Directors

Forecast to breakeven in 2025

Consensus EPS estimates fall by 31%

Forecast to breakeven in 2024

Aytu BioPharma, Inc. announced delayed 10-Q filing

Aytu BioPharma, Inc. to Report Q2, 2023 Results on Feb 14, 2023

Aytu Biopharma Regains Nasdaq Minimum Bid Price Compliance

Aytu Biopharma, Inc. Continues Availability of Adzenys XR-ODT(R) as the Only FDA-Approved Orally Disintegrating Tablet (ODT) Medication That Is Bioequivalent to Adderall XR(R) for Adhd Patients

Gary Cantrell to Retire from the Aytu BioPharma, Inc.'s Board of Directors, Effective December 31, 2022

Aytu BioPharma Receives A 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

Consensus forecasts updated

Aytu BioPharma, Inc. Announces the Passing of Michael Macaluso, Board Member

Forecast to breakeven in 2025

Aytu BioPharma, Inc. Announces Management Changes

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Aytu BioPharma, Inc. to Report Q1, 2023 Results on Nov 14, 2022

Aytu stock falls amid suspending clinical programs to save costs

Aytu Biopharma Announces Continuing Availability of Adhd Medication Adzenys Xr-Odt(R) in Response to Reported Generic Adderall(R) Xr Supply Disruptions

Consensus estimates of losses per share improve by 28%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Aytu BioScience GAAP EPS of -$0.49 misses by $0.12, revenue of $27.45M beats by $1.95M

Aytu BioPharma, Inc. to Report Q4, 2022 Results on Sep 27, 2022

Aytu BioPharma, Inc. Announces Addition of Fourth Patent License for Ar101/Enzastaurin

Aytu Biopharma adds fourth patent license for AR101 to treat rare genetic disorder

Aytu gets US patent for AR101/Enzastaurin for circulatory system disorders

Aytu BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $9.99825 million.

Aytu BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $9.99825 million.

Aytu BioPharma plunges on pricing $10M stock and warrants offering

Aytu Biopharma, Inc. Appoints Vivian Liu to Its Board of Directors and as Member of the Nominating & Corporate Governance Committee, Effective July 1, 2022

Aytu BioPharma Receives Letter from the Nasdaq

Consensus forecasts updated

Earnings Release: Here's Why Analysts Cut Their Aytu BioPharma, Inc. (NASDAQ:AYTU) Price Target To US$8.00

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Aytu BioPharma, Inc., Annual General Meeting, May 18, 2022

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$11.00

Denovo Biopharma LLC Announces Partner Aytu BioPharma Receives FDA Clearance and Orphan Drug Designation for Enzastaurin in Vascular Ehlers-Danlos Syndrome

First quarter 2022 earnings released: US$1.09 loss per share (vs US$0.35 loss in 1Q 2021)

Full year 2021 earnings released: US$3.48 loss per share (vs US$3.01 loss in FY 2020)

Insufficient new directors

Is Aytu Biopharma (NASDAQ:AYTU) Using Debt In A Risky Way?

Insufficient new directors

Insufficient new directors

Insufficient new directors

Independent Director Steven Boyd has left the company

Aytu Biopharma, Inc.(NasdaqCM:AYTU) dropped from Russell 3000E Value Index